We will continue to build our leading acute and intensive care medicine business globally by selectively investing in, partnering, licensing or acquiring innovative drug products, medical devices and diagnostic solutions
Our primary focus is on opportunities that offer a strategic fit in acute and critical care medicine, that leverage our current business
Our success in the acute and intensive care setting truly depends on our collective contributions to a combined intelligence, rigor, energy and skill of the brightest and best in the world